Agomab Advances AGMB-447 Into Phase 2 for IPF
ANTWERP, Belgium — September 14, 2026 Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447, an investigational inhaled,...
IPF
Advertisement
Avalyn Pharma Presents New AP01 Data in Pulmonary Fibrosis
BOSTON — September 8, 2026 Avalyn Pharma presented new data at the European Respiratory Society (ERS) International Congress 2026...
United Therapeutics FDA Accepts Tyvaso sNDA for IPF
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
Celea Therapeutics Advances Phase 3 Deupirfenidone Program in IPF
August 24, 2026 | Boston, Massachusetts, USA Celea Therapeutics announced that it will present new clinical development updates for...
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Advertisements
Contineum Therapeutics Affirms Phase 2 Milestones and Cash Runway
SAN DIEGO, July 30, 2026 Contineum Therapeutics, Inc. reported its second-quarter 2026 financial results while reaffirming key clinical development...
MannKind Reports Positive Phase 1b INFLO-1 IPF Results
Danbury, Conn. & Westlake Village, Calif., July 29, 2026 MannKind Corporation announced positive topline results from its Phase 1b...
Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries
Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...
Vanda Gains EMA Orphan Status for Imsidolimab in GPP
WASHINGTON, July 16, 2026 Vanda Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) at the European...
Boehringer Ingelheim Wins EU Approval for JASCAYD
INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...
Advertisement
